Odaily Planet Daily reports that Cathie Wood posted on X platform stating that, according to ARK Invest’s research, the most far-reaching application of AI will be in healthcare. Relaxed regulations are accelerating this transformation in the healthcare sector. Significant progress has been made in the science of evaluating drug efficacy, with R&D projects collecting evidence through multiple dimensions such as mechanisms of action, biomarker effects, and intermediate endpoints. This validation evidence, from mechanistic data to real-world evidence, can replace the second key trial. Historically, there has been greater regulatory flexibility in rare diseases and oncology. It is expected that the change from two trials to one will have the greatest impact in common diseases like cardiovascular and respiratory conditions, potentially saving up to $350 million per project and shortening R&D cycles by several years.